The FDA has approved drugs that target epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), rearranged during transfection (RET), the mesenchymal-epithelial transition (MET), neurotrophic tropomyosin tyrosine kinase (NTRK), and V-Raf murine sarcoma viral oncogene homolog (BRAF) for the clinical treatment in NSCLC patients (Melosky et al., 2021). Here, ROS1 is linked to non-small cell lung carcinoma.